SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioMedReports FDA Calendar: Seven Laggard Trades
LLY
|
|
|
+3.20%
in
145 days
Below are seven companies from the <font> BioMedReports.com FDA Calendar </font> database of over 200 entries, which have pending new drug decision(s) at the FDA combined with a stock price that is below its 200-day moving average (200-DMA). The list includes a balanced mix of two large-caps, two mid-caps, and three small-cap stocks which have been laggards in the overall market rally with looming regulatory catalysts in the form of FDA new drug decisions serving as potential upside catalysts. Data Source: Yahoo! Finance on 6/17/09 during late day trading. <> <font> <>http...
|
FDA, Clinical Trial Updates: GENZ, HGSI, LLY, NGSX
LLY
|
|
|
-3.44%
in
27 days
(closed on 06/17/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions...
|
Eli Lilly and Co (New York Stock Exchange)
LLY
|
|
|
+2.43%
in
203 days
http://www.lilly.com/ <> Eli Lilly and Company, incorporated in 1901, discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and 25 other countries. Eli Lilly and Company’s products are sold in approximately 135 countries. The Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. It<><><><><><><><><><><><><><>...
|
Updated FDA, Clinical Trial Calendars: CRME, MRK, LLY, PRX
LLY
|
|
|
+6.07%
in
41 days
(closed on 05/21/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/9/09. The FDA Calendar includes the following information: company name, ticker, decision ...
|
Updated Clinical Trial and FDA Decision Calendars
LLY
|
|
|
+15.74%
in
37 days
(closed on 04/10/09)
Posted by: Mike Havrilla in Untagged on Mar 04, 2009 <!-- Post Teaser Text --> <> Below are some recent updates to the BioMedReports.com -- FDA and Clinical Trial Calendars : <> 1.) Auxilium Pharma (AUXL): 3/2/09 BLA submission with priority review request for XIAFLEX (clostridial collagenase for injection), a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture. 5/2/09 is the date for FDA to accept the filing for review and decide on prior...
|
From the Blogosphere
Kiplinger’s Top 5 Stocks for Dad
|
|
|
This post was submitted by Laura Stevens of the Rosen Group.
Dads, you’re probably expecting a tie or a set of power tools this Father’s Day. If you have enough of those already (or even if you don’t), Kiplinger.com has a gift you’ll really appreciate: stock picks in companies that cater to your tastes. Kiplinger’s Top 5 Stocks for Dad are:
<>Diageo (DEO) This seller of such brands as Johnnie Walker, Smirnoff, Guinness and José Cuervo has held up better than most during the recession—thanks to a balanced portfolio of products, with higher exposure to mid-price, mainstream b<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Kiplinger’s Top 5 Stocks for Dad
|
|
|
This post was submitted by Laura Stevens of the Rosen Group.
Dads, you’re probably expecting a tie or a set of power tools this Father’s Day. If you have enough of those already (or even if you don’t), Kiplinger.com has a gift you’ll really appreciate: stock picks in companies that cater to your tastes. Kiplinger’s Top 5 Stocks for Dad are:
<>Diageo (DEO) This seller of such brands as Johnnie Walker, Smirnoff, Guinness and José Cuervo has held up better than most during the recession—thanks to a balanced portfolio of products, with higher exposure to mid-price, mainstream b<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< /><>< /><>< /><>< /><>< /><>< /><>< />< />...
|
LLY - Adjustment
<style type="text/css">.nobr br { display: none }</style>
<>
The following adjustment was made today on Eli Lilly (LLY). The following is the trade information, which includes IB commissions:
<table><tbody><tr><th>Date</th><th>Stock</th><th>Description</th><th>Transaction</th><th>Status</th><th>Stock Investment</th><th>Income Generated</th></tr><tr><td>10/23/2009</td><td>LLY</td><td>Continued Trade</td><td>STO 1 Nov09 34.00 Put @ 0.99</td><td> </td><td> </td><td>$99.00</td></tr></tbody></table>
Current Position Summary
<>
<table><tbody><tr><td>CSP Margin Used</td><td>$5,003.00</td></tr><tr><td>Inco...
|
Lilly's stock meanders, but remains a Buy
LLY
+5.67%
in
39 days
Filed under: Lilly (Eli) (LLY), Stocks to Buy  Eli Lilly & Co. (NYSE: LLY) stock has unexpectedly meandered since the June 8, 2009 Buy recommendation at a price of $34.10, but the aforementioned probably represents selected investor jitters about the likely, federal health care reform legislation.
Ignore those jitters. The major components of health care reform have not been determined as of September 30, 2009, but the pharma calculation remains the same as it was in June. The legislation will be net-positive for major pharmaceutical companies, under the thesis that there will be 30-45 million...
|
LLY - Adjustment
The following adjustment was made today on Eli Lilly (LLY):
22-Sep-09 - Interim Trade - STO 1 Oct09 34.00 Call @ 0.19 -
Current Position Summary:
Stock Investment: $5,003.00
Income Generated: $1,020.30
Percent Income Generated: 20.39%
Annualized Income Generated: 13.99%
Net Profit If Called: -$582.70
Percent Return If Called: -11.65%
Annualized Return If Called: -7.99%
Days Held to Expiration: 532 days
Trade History:
02-May-08 - Initial Stock Position - BTO 100 LLY @ 49.71 - Called
02-May-08 - Initial Call Option - STO 1 Jun08 50.00 Call @ 1.29 - Expired
10-Jun-08 - Dividend Received - DIV 100 Dividend ...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
|
|
|
|
Andy
(+313.91% risk: conservative)
|
|
|
|
|
|
|
Andy
(+313.91% risk: conservative)
|
|
|
More Resources
|
About Eli Lilly and Company
- Answers.com
